Evidence map›Paper›PMID 40351093›Full record

ArticleClinical pharmacology and therapeutics2025

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y

Ashley N Springer, Leah A Alicea, Yemi Gafari, Tayler B Smith, Sheryl Lynch, Amy M Breman, Jennelle C Hodge, Victoria M Pratt, Nicholas R Powell, Rolf P Kreutz and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ashley N SpringerDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0009-0000-7911-2758
Leah A AliceaDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Yemi GafariDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Tayler B SmithDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Sheryl LynchDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Amy M BremanDivision of Diagnostic Genetics and Genomics, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jennelle C HodgeDivision of Diagnostic Genetics and Genomics, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-1770-4042
Victoria M PrattDivision of Diagnostic Genetics and Genomics, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-2871-5051
Nicholas R PowellDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Rolf P KreutzDivision of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Daniel P KoboldIndiana University Health, Indianapolis, Indiana, USA.
Michael T EadonDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-3066-2876
Emma M Tillman *Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0001-8019-9811
Tyler Shugg *Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-5784-3565
Todd C Skaar *Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-3849-374X

Funding

Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint InhibitorsK23GM147805 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI Tyler A Shugg · 2022 to 2026
$836k
NIGMS NIH HHS K23 GM147805NIGMS NIH HHS L30 GM151735
6 · The paper itself

Abstract

P2Y

Indexed as

Cytochrome P-450 CYP2C19Decision Support Systems, ClinicalPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAgedClopidogrelElectronic Health RecordsFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPractice Patterns, Physicians'ClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Identifiers

PMID40351093
PMCPMC12272324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.